Further Evidence that Remdesivir Has Limited Benefit for Patients Hospitalized with COVID-19

In a single-country add-on study to the international SOLIDARITY trial, remdesivir showed no clinical or antiviral benefit.

Based on the ACTT-1 trial (NEJM JW Infect Dis Dec 2020 and N Engl J Med 2020; 383:1813), remdesivir was the first antiviral drug approved by the FDA as a treatment for SARS-CoV-2 infection and is recommended for treatment of hospitalized patients who require supplemental oxygen but not mechanical ventilation (NIH COVID-19 Treatment Guidelines). However, other studies, including the WHO-SOLIDARITY trial, showed no benefit of remdesivir treatment (N Engl J Med. 2021;384:497). Now, investigators in Norway report additional outcome and virologic data from an independent add-on to SOLIDARITY.

One hundred eighty-one patients participating in SOLIDARITY at 23 hospitals in Norway were randomized to remdesivir, hydroxychloroquine, or local standard o…

Reviewing Author

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Further Evidence that Remdesivir Has Limited Benefit for Patients Hospitalized with COVID-19

Topics

Reviewing Author